Showing results (741-750 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|May 9, 2021
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension studyJordana E Hoppe, Mark Chilvers, Felix Ratjen, et al.
The Lancet. Respiratory Medicine|May 9, 2021
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entityMarcin F Osuchowski, Martin S Winkler, Tomasz Skirecki, et al.
The Lancet. Respiratory Medicine|July 20, 2025
The global burden of COPD: epidemiology and effect of prevention strategiesMaria Montes de Oca, Rogelio Perez-Padilla, Bartolome Celli, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
The Lancet. Respiratory Medicine|November 30, 2025
Trajectories of prematurity-associated lung disease: lifelong lung healthCassidy Du Berry, Diane M Gray, Amber Bates, et al.
The Lancet. Respiratory Medicine|February 7, 2025
Acute pulmonary embolism in children and adolescents in the USA (2016 and 2019): a nationwide retrospective cohort studySimon Wolf, Luca Valerio, Nils Kucher, et al.
The Lancet. Respiratory Medicine|February 23, 2025
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patientsFranck F Rahaghi, Marc Humbert, Marius M Hoeper, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trialsClaire Keating, Lael M Yonker, François Vermeulen, et al.
The Lancet. Respiratory Medicine|January 12, 2025
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021-23)Sarah F Hak, Valérie D V Sankatsing, Joanne G Wildenbeest, et al.
The Lancet. Respiratory Medicine|March 20, 2025
Decisions to withdraw or withhold life-sustaining therapies in patients with and without acute brain injury: a secondary analysis of two prospective cohort studiesShaurya Taran, Kuan Liu, Victoria A McCredie, et al.
Pageof 104